Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHD-286 for POU2F3-Positive Small-Cell Lung Cancer
NCT07551635Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camibirstat in small cell lung cancer (SCLC), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
camibirstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07551635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07551635.